Drug development

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug. The entire process – from concept through preclinical testing in the laboratory to clinical trial development, including Phase I–III trials – to approved vaccine or drug typically takes more than a decade. Broadly, the process of drug development can be divided into preclinical and clinical work. Pre-clinical development New chemical entities (NCEs, also known as new molecular entities or NMEs) are compounds that emerge from the process of drug discovery. These have promising activity against a particular biological target that is important in disease. However, little is known about the safety, toxicity, pharmacokinetics, and metabolism of this NCE in humans. It is the function of drug development to assess all of these parameters prior to human clinical trials. A further major objective of drug development is to recommend the dose and schedule for the first use in a human clinical trial ("first-in-human" [FIH] or First Human Dose [FHD], previously also known as "first-in-man" [FIM]). In addition, drug development must establish the physicochemical properties of the NCE: its chemical makeup, stability, and solubility. Manufacturers must optimize the process they use to make the chemical so they can scale up from a medicinal chemist producing milligrams, to manufacturing on the kilogram and ton scale. They further examine the product for suitability to package as capsules, tablets, aerosol, intramuscular injectable, subcutaneous injectable, or intravenous formulations. Together, these processes are known in preclinical and clinical development as chemistry, manufacturing, and control (CMC).

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (7)

Related people (5)

Related concepts (29)

Related courses (22)

Related lectures (78)

Drug development

Clinical trial

Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison. Clinical trials generate data on dosage, safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought.

Preclinical development

In drug development, preclinical development, also termed preclinical studies or nonclinical studies, is a stage of research that begins before clinical trials (testing in humans) and during which important feasibility, iterative testing and drug safety data are collected, typically in laboratory animals. The main goals of preclinical studies are to determine a starting, safe dose for first-in-human study and assess potential toxicity of the product, which typically include new medical devices, prescription drugs, and diagnostics.

CH-635: Chemical Biology Seminar Series 1

PhD students can broaden their horizon in the field of chemical biology by listening to 14 talks by speakers who talk about their recent research. The PhD students get the opportunity to also personal

BIO-494: Scientific project design in drug discovery

The goal of this course is to instruct the student how fundamental scientific knowledge can be applied for drug discovery and development. We will demonstrate these principles with examples, including

BIO-487: Scientific project design in translational neurosciences

The goal of this course is to instruct the student how fundamental scientific knowledge, acquired through the study of fundamental disciplines, including biochemistry, genetics, pharmacology, physiolo

Tuberculosis (TB), whose etiological agent is Mycobacterium tuberculosis (M. tuberculosis), has plagued humanity since antiquity. Even with chemotherapy available today, TB is the leading cause of dea

EPFL2018

Sirtuin 2 Deficiency Increases Bacterial Phagocytosis by Macrophages and Protects from Chronic Staphylococcal Infection

Johan Auwerx, Tytti Heinonen, Marc Pfefferlé

Sirtuin 2 (SIRT2) is one of the seven members of the family of NAD(+)-dependent histone deacetylases. Sirtuins target histones and non-histone proteins according to their subcellular localization, inf

Frontiers Media Sa2017

Deguelin exerts potent nematocidal activity via the mitochondrial respiratory chain

Johan Auwerx, Martinus Gijs, Matteo Cornaglia, Laurent Mouchiroud, Abdul Jabbar

As a result of limited classes of anthelmintics and an over-reliance on chemical control, there is a great need to discover new compounds to combat drug resistance in parasitic nematodes. Here, we sho

Federation Amer Soc Exp Biol2017

Total Synthesis: Strategies and Impact

Explores total synthesis of natural products, strategies, impact on science and society, drug development, and biological studies.

Parkinson's Disease Drug Development

Explores drug development strategies for Parkinson's Disease, including target identification and potential therapeutic strategies.

Preclinical Animal Models: Selection & Rationale

Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.